Haemonetics Corp. shares rose 6.6% to $96.21 in pre-market trading after the medical technology firm formalized a non-exclusive supply agreement with CSL Plasma, one of the world’s largest plasma collection operators.
The agreement, disclosed in an 8-K filing, permits CSL Plasma to deploy Haemonetics’ NexSys PCS devices with Persona PLUS technology across its U.S. plasma collection centers. No minimum purchase commitments are included in the terms. The news follows Haemonetics’ Q1 FY2027 earnings report, which showed revenue of $339.4 million, exceeding the consensus estimate of $327.9 million. Adjusted earnings per share came in at $1.14, above the $1.08 forecast.
For the full fiscal year 2027, Haemonetics raised its reported revenue growth guidance to a range of 5% to 8%, up from prior expectations. The stock had previously traded near its 52-week high of $92.25 and recovered from a 52-week low of $47.31.
Analysts responded with mixed but largely positive revisions. Raymond James lifted its price target to $105 from $95, while Baird and Barrington each raised their targets to $96 and $95, respectively. Mizuho maintained a Buy rating, whereas Citi initiated coverage with a Hold recommendation.
In broader pre-market activity, the S&P 500 declined 0.4%, the Dow was barely positive, and the NASDAQ fell 1.2%.
